Cargando…
The US Food and Drug Administration’s drug safety recommendations and long-acting beta2-agonist dispensing pattern changes in adult asthma patients: 2003–2012
BACKGROUND: Emerging safety issues associated with long-acting beta(2)-agonist (LABA) have led to multiple regulatory activities by the US Food and Drug Administration (FDA) since 2003, including Drug Safety Communications (DSCs) in 2010. These DSCs had three specific recommendations for the safe us...
Autores principales: | Zhou, Esther H, Seymour, Sally, Goulding, Margie R, Kang, Elizabeth M, Major, Jacqueline M, Iyasu, Solomon |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5360406/ https://www.ncbi.nlm.nih.gov/pubmed/28356763 http://dx.doi.org/10.2147/JAA.S124395 |
Ejemplares similares
-
The Effect of FDA Drug Safety Communications on Patterns of Tiotropium Dispensing: A U.S. Health Plan Claims Database Study
por: Major, Jacqueline M., et al.
Publicado: (2018) -
Drug Utilisation Study in a Tertiary Care Center: Recommendations for Improving Hospital Drug Dispensing Policies
por: Mittal, Niti, et al.
Publicado: (2014) -
Use of surrogate outcomes in US FDA drug approvals, 2003–2012: a survey
por: Yu, Tsung, et al.
Publicado: (2015) -
Loss of Asthma Control in Pediatric Patients after Discontinuation of Long-Acting Beta-Agonists
por: R. O'Hagan, Adrian, et al.
Publicado: (2012) -
Add-on Therapy for Symptomatic Asthma despite Long-Acting Beta-Agonists/Inhaled Corticosteroid
por: Dreher, Michael, et al.
Publicado: (2018)